Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

Journal:

Nature Communications

Published:

2025-10-06

DOI:

10.1038/s41467-025-63960-8

Affiliations:

25

Authors:

24

Go to article

Institutions	Authors	Share
Bristol-Myers Squibb, United States of America (USA)	5.000000	0.21
The University of Texas MD Anderson Cancer Center, United States of America (USA)	3.000000	0.13
IRCCS Istituto Oncologico Veneto (IOV), Italy	1.000000	0.04
USC Norris Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
Candiolo Cancer Institute (FPO-IRCCS), Italy	1.000000	0.04
University Hospital of Modena, Italy	1.000000	0.04
Westmead Hospital (WSLHD), Australia	1.000000	0.04
Duke University Health System, United States of America (USA)	1.000000	0.04
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.04
Institute Jules Bordet, ULB, Belgium	1.000000	0.04
Vanderbilt University Medical Center (VUMC), United States of America (USA)	1.000000	0.04
University Hospital, VUB, Belgium	1.000000	0.04
Tasman Health Care, Australia	1.000000	0.04
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.04
Novant Health, United States of America (USA)	1.000000	0.04
Minnesota Oncology, United States of America (USA)	1.000000	0.04
Saint Antoine Research Center (CRSA), France	0.500000	0.02
SIRIC CURAMUS, France	0.500000	0.02
St. Vincent's University Hospital, Ireland	0.500000	0.02
Cancer Trials Ireland, Ireland	0.500000	0.02

Interested in Oncology and Carcinogenesis?